Publications

Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014. by Pfaller MA, Flamm RK, Jones RN, Farrell DJ and Mendes RE published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5393-5399

Pharmacokinetics-pharmacodynamics of tazobactam in combination with piperacillin in an in vitro infection model. by Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG published in Antimicrob. Agents. Chemother. 2016; 60 (4): 2075-2080

Comparison of BD Max StaphSR and BD Max MRSAXT for screening of Staphylococcus aureus clinical isolates collected from hospitals in the United States. by Mendes RE, Watters AA, Rhomberg PR, Farrell DJ and Jones RN published in J. Clin. Microbiol. 2016; 54 (6): 1668-1669

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): Evolving resistance mechanisms with stable susceptibility rates. by Mendes RE, Hogan PA, Jones RN, Sader HS and Flamm RK published in J. Antimicrob. Chemother. 2016; 71 (7): 1860-1865

In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. by Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S and Sader HS published in Antimicrob. Agents. Chemother. 2016; 60 (7): 4407-4411

β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates. by Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (3): 1328-1335

Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2016; 71 (12): 3453-3458

Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226. by Jones RN, Fedler KA, Scangarella-Oman NE, Ross JE and Flamm RK published in Antimicrob. Agents Chemother. 2016; 60 (7): 4404-4406

In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013). by Huband MD, Castanheira M, Farrell DJ, Flamm RK, Jones RN, Sader HS and Mendes RE published in Int. J. Antimicrob. Agents. 2016; 47 (6): 495-499

In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. by Flamm RK, Rhomberg PR, Huband MD and Farrell DJ published in Antimicrob. Agents Chemother. 2016; 60 (10): 6381-6385

In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. by Flamm RK, Rhomberg PR, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2016; 86 (1): 66-69

Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). by Flamm RK, Castanheira M, Streit JM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2016; 85 (3): 352-355

International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for fusarium species identified by molecular methods for the CLSI broth microdilution method. by Espinel-Ingroff A, Colombo AL, Cordoba S, Dufresne PJ, Fuller J, Ghannoum M, Gonzalez GM, Guarro J, Kidd SE, Meis JF, Melhem TM, Pelaez T, Pfaller MA, Szeszs MW, Takahaschi JP, Tortorano AM, Wiederhold NP and Turnidge J published in Antimicrob. Agents. Chemother. 2016; 60 (2): 1079-1084

Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014). by Duncan LR, Smart JI, Flamm RK, Sader HS, Jones RN and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2016; 86 (3): 300-302

Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the USA (2013-2014). by Duncan LR, Sader HS, Flamm RK, Jones RN and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2016; 86 (3): 303-306

Effect of the β-Lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. by Castanheira M, Rhomberg PR, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5454-5458

Changes in the frequencies of β-lactamase genes among Enterobacteriaceae isolates in U.S. Hospitals, 2012 to 2014: Activity of ceftazidime-avibactam tested against β-lactamase-producing isolates. by Castanheira M, Mendes RE, Jones RN and Sader HS published in Antimicrob. Agents. Chemother. 2016; 60 (8): 4770-4777

Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program during 2014-2015. by Castanheira M, Griffin MA, Deshpande LM, Mendes RE, Jones RN and Flamm RK published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5623-5624

High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center. by Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, Prince RA, Bhatti MM, Rolston KV, Jones RN, Castanheira M and Chemaly RF published in Clin. Infect. Dis. 2016; 63 (7): 954-958

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) P. aeruginosa Isolates from Hospitalized Patients with Bloodstream Infections and Pneumonia in European Medical Centres. Lead author: D Shortridge, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1246

Telavancin Activity against a Global Collection of Staphylococcus aureus Clinical Isolates (2013-2015). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1356

β-lactamase Characterization of Baseline Gram-Negative Pathogens from a Phase 3 Trial of Ceftazidime-Avibactam (CAZ-AVI) for the Treatment of Nosocomial Pneumonia. Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P0408

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Gram-Negative Organisms Collected from European Medical Centres. Lead author: D Shortridge, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1271

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Gram-Negative Organisms Collected from Latin America Medical Centres. Lead author: LR Duncan, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1272

Dalbavancin Tested against Staphylococcus aureus Isolates with Decreased Susceptibility to Glycopeptides and/or Lipopeptides from European Hospitals (2012-2016). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna Austria
# P0138

Activity of Tedizolid against Methicillin-Susceptible and -Resistant Staphylococcus aureus Pathogens Isolated from Patients in European Centres and Surrounding Regions. Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1344

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in Europe and Surrounding Areas (2014-2015). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1502

Plazomicin Activity against European Enterobacteriaceae Isolates Carrying Aminoglycoside-Modifying Enzymes and 16S rRNA Methylases. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1281

In vitro Activity of Omadacycline and Comparators against Staphylococci, and Enterococci (including resistant organism subsets) from Patients in European medical Centres during 2016: Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1262

In vitro Activity of Omadacycline and Comparators against Gram-Negative Bacterial Isolates Collected from Patients in European Medical Centres (2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1253

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates Collected during 2014-2015 from European Countries. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1286

Monitoring Echinocandin and Azole Susceptibility in a Global Collection of Invasive Fungal Isolates. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, 2017, Vienna, Austria
# P1748

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary ABSSSI Isolates from Europe and Surrounding Areas (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1351

Dalbavancin Tested against Staphylococcus aureus Isolates with Decreased Susceptibility to Glycopeptides and/or Lipopeptides from European Hospitals (2012-2016). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, 2017, Vienna, Austria
# P0138

Antimicrobial Activity of Ceftobiprole versus Other Currently Marketed Cephalosporins and β-Lactams When Tested against Contemporary Gram-Positive and -Negative Organisms Collected from Europe (2015). Lead author: RK Flamm, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P0146

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Contemporary (2013-2015) Gram-Negative Organisms Collected from United States Medical Centers. Lead author: HS Sader, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1291

Activity of Plazomicin and Comparator Agents Tested against Recent Clinical Isolates Collected in Asia-Pacific, Europe, and Latin America. Lead author:M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, 2017, Vienna, Austria
# P1280

Ceftaroline Activity against MDR Streptococcus pneumoniae Subsets from United States Medical Centers (2014), Lead author: Farrell DJ, presented at American Thoracic Society 2016 (ATS 2016), May 13-18, 2016, San Francisco, California, USA
Poster A2117

Serotype Distribution of Streptococcus pneumoniae Recovered from Adults in the United States and Selected European Countries (2009-2013), Lead author: Mendes RE, presented at 10th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-10), June 26-30, 2016, Glasgow, Scotland

Ceftazidime-avibactam Activity against P. aeruginosa from Intensive Care (ICU) and Non-ICU Patients, Lead author: Sader HS, presented at Society of Critical Care Conference, 46th Critical Care Congress, January 21-25, 2017, Honolulu, Hawaii, USA

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia, Lead author: Sader HS, presented at Society of Critical Care Conference, 46th Critical Care Congress, January 21-25, 2017, Honolulu, Hawaii, USA

Surveillance of Ceftolozane/Tazobactam Antimicrobial Activity Tested Against Contemporary Gram-Negative Organisms and Streptococcus pneumoniae Isolated in Australia

Analysis of MIC Relationships Between Tedizolid, Linezolid, and Vancomycin Tested Against Staphylococcus aureus and Enterococcal Clinical Isolates from US and European Hospitals (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1829

In Vitro Activity of Tedizolid in Comparison With Other Oral and Intravenous Agents Against a US Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1821

Activity of Pexiganan when Tested against Contemporary Gram-Positive, Gram-Negative Bacteria and Yeast Collected from North America, Europe and Japan, Lead author: Flamm, RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1826

Prevalence of Main Gram-positive Pathogens Causing Bloodstream Infections in US Medical Centers (2010-2015) and Analysis of Oritavancin In Vitro Activity, Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 303

Activity of Omadacycline when Tested against Gram-Positive Bacteria Isolated from Patients in the USA During 2015 as Part of a Global Surveillance Program, Lead author: Flamm, RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1827

Activity of Linezolid when Tested against Gram-Positive Isolates from the USA (Linezolid Experience and Accurate Determination of Resistance [LEADER]) from 2015, Lead author: Flamm RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 2007

Activity of Isavuconazole and Comparator Mould-Active Triazoles Tested against Contemporary Invasive Mould Isolates, Lead author: Pfaller MA, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1621

In Vitro Activity of ZTI-01 (Fosfomycin for Injection) against Contemporary Gram-negative and Gram-positive Isolates – A Comparison of Inter-method Testing, Lead author: Flamm RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1833